EUCTR2017-002293-39-NL进行中（未招募）1 期
MULTICENTER, RANDOMIZED STUDY, TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (DISPARITY OF HLA EPLETS AND ELISPOT-?) TO OPTIMIZE IMMUNOSUPPRESSIVE TREATMENT IN LIVING DONOR KIDNEY RECIPIENTS - BIOIMM
ORIOL BESTARD0 个研究点目标入组 164 人开始时间: 2020年4月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Adult men and women (= 18 years).
- •2) Receptors of a first kidney transplant from a living donor.
- •3) AB0 compatible transplant.
- •4) Patients with a calculated PRA <= 75% by solid-phase technique and absence of current or historical donor specific class I or class II anti-HLA antibodies (DSA).
- •5) Patients who agree to participate in the Assay by signing the Informed Consent specific to this study.
- •6) Potentially fertile women should use high-reliability contraceptive methods (Pearl-Index <1) to prevent pregnancy for the duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF). Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not post-menopausal (defined as amenorrhoea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml). Potentially Fertile Women should have a pregnancy test with a negative result performed within 72 hours prior to the start of the trial.
- •7) Sexually active (including vasectomized) males who are receiving MMF treatment should accept the use of barrier contraception during MMF treatment and during the 90 days thereafter. Potentially fertile couples of these patients should use a reliable method of contraception during the same period, in order to minimize the risk of pregnancy.
- •8) Patients should agree not to donate blood during MMF treatment and for 6 weeks thereafter. Males should not donate sperm during MMF treatment and up to 90 days after finishing MMF.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 64
排除标准
- •1) Patients with a calculated PRA > 75% by solid-phase technique and/or presence of current or historical donor specific class I or class II anti-HLA antibodies (DSA).
- •2) Cross Match positive result.
- •3) Patients receiving a graft from a deceased donor.
- •4) Patients who have undergone a previous solid organ transplant (including renal transplantation) or who are going to receive another solid organ transplant concomitantly.
- •5) Patients with any of the following basic kidney diseases:
- •Primary focal and segmental glomerulosclerosis
- •Atypical Uremic Hemolytic Syndrome (aHUS) / Thrombotic Thrombotic Syndrome Thrombocytopenic.
- •6) Patients with active Hepatitis B virus (HBV) infection and / or active Hepatitis C virus infection (positive PCR result) at the time of transplantation.
- •7) Patients with known Human Immunodeficiency Virus (HIV) infection.
- •8) Patients with active systemic infection requiring continued antibiotic administration.
- •9) Patients with any neoplasia except localized skin cancer receiving appropriate treatment.
- •10) Patients with severe anemia (hemoglobin <6g / dl), leukopenia (WBC <2500 / mm3) and / or thrombocytopenia (platelets <80,000 / mm3).
- •11) Hemodynamically unstable patients with hemoglobin levels> 6g / dl.
- •12) Patients with intestinal pathology or severe diarrhea that may decrease absorption according to medical criteria.
- •13) Patients with known hypersensitivity to any of the drugs used in this study.
- •14) Patients who have received any investigational drug within 30 days prior to their inclusion in this study.
- •15) Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or have a positive pregnancy test at the time of enrollment.
- •16) Patients who are legally detained in an official institution.
研究者
相似试验
进行中（未招募）
1 期
STUDY TO OPTIMIZE IMMUNOSUPPRESSIVE MEDICATION AS A RESULT OF TWO MARKERS IN PATIENTS WHO RECEIVE A RENAL TRANSPLANTATION OF A LIVE DONOREUCTR2017-002293-39-ESORIOL BESTARD
进行中（未招募）
不适用
MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH ENDOCRINE TREATMENT COMPARED TO ENDOCRINE TREATMENT ALONE, IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC CANCER WITH INDICATION OF HORMONOTHERAPY AS FIRST-LINE TREATMENTPostmenopausal women with advanced or metastatic cancer with indication of hormonotherapy as first-line treatment.MedDRA version: 14.0Level: LLTClassification code 10006275Term: Breast metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10006212Term: Breast carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-002841-19-DEGrupo Español de Investigación en Cáncer de Mama (GEICAM)378
尚未招募
不适用
Multicenter randamized study for evaluating the effect of dantrolene aganst heart failure and arrhythmiaheart failureJPRN-UMIN000022756Yamaguchi University Graduate School of Medicine100
进行中（未招募）
不适用
A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100
已完成
不适用
A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.ephrosclerosisJPRN-UMIN000007130Omihachiman Community Medical Center77